Seroxat
GSK loses £37m appeal over pay-to-delay tactics to block Seroxat competition
March 9, 2018Medical Communications, Sales and Marketing GSK, Pay to delay, Seroxat, antidepressant, pay-to-delay, pharma
GlaxoSmithKline has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to …
GSK cancels sale of established products
December 5, 2014Medical Communications, Sales and Marketing FDA, GSK, Paxil, Seroxat, Zantac, bribery, cuts, imitrex
GlaxoSmithKline has decided not to sell off several of its ageing brands in the face of continuing business problems. The …
GSK sales up – impact of China allegations to follow
July 24, 2013Sales and Marketing GSK, Q2, Seretide, Seroxat, Witty, bribery, transparency
GlaxoSmithKline has reported a modest rise in sales but the fallout from China’s bribery probe dominates the firm’s release of …
China accuses GSK of large scale bribery
July 12, 2013Medical Communications, Research and Development, Sales and Marketing Avandia, China, GSK, Seroxat
Health officials in China say they have found evidence GSK tried to generate sales and raise drug prices by bribing …
GSK faces £2.6 billion fine
April 19, 2013Sales and Marketing GSK, Seroxat, paroxetine
GlaxoSmithKline could be fined £2.6 billion after the Office of Fair Trading (OFT) alleged it paid generics firms to slow …
GSK takes £1.58bn hit from legal disputes
July 16, 2010Sales and Marketing Avandia, GlaxoSmithKline, Paxcil, Seroxat
GlaxoSmithKline is set to pay £1.58 billion to settle three long-standing legal disputes, including litigation costs for its troubled diabetes …
